首页> 外文期刊>Prostate Cancer and Prostatic Diseases >Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial
【24h】

Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial

机译:高危前列腺癌的超分割同时整合增强疗法(IMRT-SIB)与盆腔淋巴结照射和同时进行雄激素剥夺治疗:一项前瞻性II期试验的结果

获取原文
           

摘要

ObjectiveThe approach for treating high-risk prostate cancer still presents different unresolved issues. We report the safety and efficacy of a radiation therapy strategy based on the combination of moderate hypofractioned simultaneous integrated boost (SIB) and Image Guidance.Materials and methodsIn this phase II trial of patients with high-risk prostate cancer, Image Guided SIB-IMRT plans (Simultaneous Intensity Modulated - Intensity Modulated Radiotherapy) were delivered between 2009 and 2012. All patients enrolled (41) received in 25 fractions a total dose of 67.5?Gy (2.7?Gy/fraction) to the prostatic volume, 56.25?Gy (2.25?Gy/fraction) to the seminal vescicles, and 50?Gy (2.0?Gy/fraction) to the pelvic lymph nodes (LN) chains with concurrent androgen deprivation therapy (ADT). The image-guided radiotherapy (IGRT) procedure was performed using three gold seeds. RTOG late gastrointestinal and genitourinary toxicities and 6-year biochemical relapse-free survival (BRFS) were assessed in combination of their statistical correlation with clinical factors and dosimetric parameters.ResultsRate of late genitourinary toxicity grade 2 was 9.8%, while rates of late gastrointestinal toxicity were 14.6% and 2.4%, for grade 1 and 2, respectively. Diabetes and maximum doses to rectum appeared to be statistically relevant risk factors for late rectal toxicity. Five-year BRFS was 95.1%.ConclusionsIn our study, we observed positive results in terms of toxicity and good efficacy in a cohort of high-risk prostate cancer patients treated with a multimodality therapy approach comprising hypofractionation, irradiation of pelvic nodes (common iliac nodes included), and concurrent ADT. These favorable results may merit further investigation in a phase III randomized trial to confirm that whole pelvic radiation therapy (WPRT) combined with moderate hypofractionation and ADT could be performed safely and effectively.
机译:目的治疗高危前列腺癌的方法仍然存在其他未解决的问题。我们报告了基于中度次分割同时增强(SIB)和影像指导相结合的放射治疗策略的安全性和有效性。材料和方法在此II期临床试验的高危前列腺癌患者中,影像引导式SIB-IMRT计划(同时调强-调强放疗)于2009年至2012年之间进行。所有入组患者(41名)分25剂接受总剂量为67.5?Gy(2.7?Gy /部分)的前列腺液,即56.25?Gy(2.25)。并用雄激素剥夺疗法(ADT)将50 Gy(2.0 Gy /馏分)注入精囊囊,将50 Gy(2.0μGy/馏分)转移至盆腔淋巴结(LN)链。使用三枚金种子进行图像引导放射治疗(IGRT)。结合临床因素和剂量学参数,对RTOG晚期胃肠道和泌尿生殖道毒性以及6年生化无复发生存率(BRFS)进行了评估。结果晚期胃肠道毒性反应的2级率为9.8%,而晚期胃肠道毒性的发生率1年级和2年级分别为14.6%和2.4%。糖尿病和直肠最大剂量似乎是晚期直肠毒性的统计学相关危险因素。五年期BRFS为95.1%。结论在我们的研究中,我们观察了一组高风险前列腺癌患者的毒性和良好疗效方面的积极结果,这些患者接受了包括分割术,盆腔结节(常见(结)的多模式治疗方法(包括)和并发ADT。这些良好的结果可能值得在III期随机试验中进行进一步研究,以确认可以安全有效地进行全盆腔放射治疗(WPRT)结合中度低分割和ADT。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号